Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Muscarinic Receptor Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Muscarinic Receptor Antagonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Muscarinic receptors are the sites for the neurotransmitters of the parasympathetic autonomic nervous system, acetylcholine, thus muscarinic receptors are responsible for responses including, cardiac slowing, contraction of smooth muscles, vasodilation and increased secretion from exocrine glands. Muscarinic receptor antagonists act on these 5 subtypes of muscarinic receptors i.e., M1, M2, M3, M4, and M5, and induce actions like bronchodilation, reduced gastric acid, reduce secretions from glands, inhibition of bladder contraction, and others. Muscarinic receptor antagonists are indicated for conditions such as chronic obstructive pulmonary disease, overactive bladder, motion sickness, asthma, and myopia. Boehringer Ingelheim, Novartis, AstraZeneca, LENZ Therapeutics, Orient Europharma, and GSK are some of the major market players in muscarinic receptor antagonists. Moreover, there are drugs in the pipeline of pharmaceutical companies for other health conditions.
Key Market Developments:
Approved Drug Molecules and Brand Names for Muscarinic Receptor Antagonists:
Drugs under the Pipeline for Muscarinic Receptor Antagonists:
Clinical Activity and Developments of Muscarinic Receptor Antagonists:
As of June 2023, more than 30 companies have approximately 29 molecules for above 549 diseases. For these molecules, more than 493 clinical trials are being conducted by players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Glycopyrrolate (PT001) |
19 |
|
Batefenterol (GSK961081) |
13 |
|
Darotropium bromide (GSK233705) |
11 |
|
Xanomeline/Trospium (KarXT) |
11 |
|
Aroxybutynin/Atomoxetine (AD109) |
6 |
|
AZD2115 |
6 |
|
Easyhaler Tiotropium (Tiotropium bromide) |
5 |
|
Navafenterol (AZD8871) |
5 |
|
ASM-024 |
4 |
|
Diphenhydramine/Lorazepam/Zolpidem (SM-1) |
4 |
|
Oxybutynin/Atomoxetine (AD036) |
4 |
|
Fluticasone/Batefenterol (FF/GSK-961081) |
3 |
|
Aceclidine/Tropicamide (PRX-100) |
2 |
|
Tiotropium bromide inhalation (VR410) |
2 |
|
Trospium chloride inhalation (ALKS 27) |
2 |
|
AZD8999 |
1 |
|
CHF6366 |
1 |
|
Enablex (Darifenacin) |
1 |
|
Afacifenacin fumarate (SMP-986) |
1 |
|
Atropine (CBT-009) |
1 |
|
Atropine (OT-101 ophthalmic solution) |
1 |
|
Atropine Sulfate (DE-127) |
1 |
|
Clonidine/Oxybutynin (OP-014) |
1 |
|
Glycopyrronium bromide (PSX-1002) |
1 |
|
Ketamine/Scopolamine |
1 |
Muscarinic receptor antagonists such as Darifenacin, and Tolterodine are used for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Glycopyrronium is indicated to reduce the volume and acidity of gastric secretions, and airway secretion, and block cardiac inhibitory reflexes during the induction of anesthesia and intubation. Aclidinium is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Additionally, there are drug molecules in the clinical trial phases for conditions like myopia, presbyopia, and others.
According to the World Health Organization at present 2.2 billion people around the world have vision impairment. According to a research report, the global prevalence of gastric secretion-related diseases such as peptic ulcer was approximately 8.09 million, representing a 25.82% increase from 1990, where the highest age-standardized prevalence rate was in South Asia. All these growing burdens of diseases indicate a high growth potential for the muscarinic receptor antagonist market. AstraZeneca’s Breztri had a total product sale of US$ 398 million in 2022, including, US$ 239 million in the USA, US$ 92 million in the emerging markets, US$ 34 million in Europe, and US$ 34 million in the rest of the world. Boehringer Ingelheim’s Spiriva had net sales of US$169 million in 2021 and witnessed an insignificant increase in sales of US$ 170 million in 2022 due to currency reasons.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Tolterodine, Fesoterodine, Stiolto Respimat (Olodaterol/Tiotropium Fdc), Anoro Ellipta (Umeclidinium/Vilanterol), Tiotropium Bromide Dry Powder Inhaler, and Ultibro (Glycopyrronium/Indacaterol) are some of the approved muscarinic receptor antagonists.
Boehringer Ingelheim, Novartis, AstraZeneca, LENZ Therapeutics, Orient Europharma, and GSK are some of the major market players in muscarinic receptor antagonists.
Major indications for muscarinic receptor antagonists are chronic obstructive pulmonary disease, overactive bladder, motion sickness, asthma, and myopia.
There are a total of 28 molecules in the clinical development phases for muscarinic receptor antagonists.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.